Both Joe Rogan and Tim Ferriss have both gone on the record as supporters of responsible psychedelics use.
We can’t understate how powerful these voices are.
Their audiences are massive.
The Tim Ferriss Show is one of the largest podcasts in the world. It has been downloaded by listesteners more than 500 million times.
The Joe Rogan Experience surpasses that. It gets more than 200 million downloads every month and streaming giant Spotify recently paid $100 million to get exclusive rights to Rogan’s podcast.
The two new media giants have become strong influencers of public opinion. And when they are both on the same page, you better pay attention.
They are just prominent members of the psychedelics user base that the National Center for Biotechnology Information says has surpassed 30 million active psychedelics users in the United States.
Joe Rogan has talked to multiple guests about their experiences using Dimethyltryptamine (DMT).
DMT is a drug similar to LSD, but doesn’t last as long.
It is the active ingredient in ayahuasca and has neuroprotective/neurorestorative properties.
It is also the focus of one of the early movers in the psychedelics sector, MindMed (CAN :MMED / US:MMEDF).
DMT is going through or has completed three clinical studies to test its therapeutic effectiveness for treatment-resistant depression and substance dependence.
Specifically, MindMed has started an FDA Phase 1 clinical study of DMT at a lab in Switzerland.
Joe Rogan and his massive audience will be hearing more about these in the future and Rogan has really brought DMT into the mainstream.
Additionally, he has exposed his millions of followers to the idea of psychedelics through long form interviews with leaders in the field of psychedelics such as:
Michael Pollan (Author of How To Change Your Mind NYT #1 Best Seller)
Michael Pollan is author of five New York Times Best Sellers and he set out to research how LSD and psilocybin (magic mushrooms) are being used to provide relief to people suffering from difficult-to-treat conditions such as depression, addiction and anxiety.Hamilton Morris (Hamilton’s Pharmacopeia on VICELAND)
Hamilton is an American journalist and pharmacological researcher. He is known for his VICE television series Hamilton's Pharmacopeia, in which he investigates the chemistry, history, and cultural impact of various psychoactive drugs.And Psychiatrist Dr. Dan Engle (KUYA Institute for Transformational Medicine, Onnit Labs)
Dr. Engle's background in integrative psychiatry, neurocognitive restoration, peak performance medicine and psychedelic research, Dr. Dan Engle helps individuals shift from illness and trauma to health and happiness.Hamilton Morris and Dr. Dan Engle are taking it even further, joining the Scientific Advisory of new psychedelic company Mind Cure Health Inc (OTCQB: MCURF; CSE: MCUR)
SEE: Mind Cure Assembles Cast For Psychedelic Drug Success
But these examples are just part of the early-stage potential of psychedelics that’s rapidly advancing.
Tim Ferriss is probably deeper into the psychedelics sector than most others and has been for years.
The top podcast, best-selling author, and venture capitalist, has been an active campaigner for research into psychedelics.
He helped the Multidisciplinary Association for Psychedelic Studies (MAPS) raise $30 million to advance the organization’s clinical research into the active ingredient in “magic mushrooms.”
$30 million is a massive amount of money.
But Ferriss is just part of a much bigger crowd of big money behind the surge in psychedelics research.
As we stated in Why Are Silicon Valley AND Wall Street Backing Psychedelic Drugs?:
Silicon Valley’s interest in psychedelic drugs is understandable.
These maverick entrepreneurs are driven by science, not politics. They are not afraid to target politically unpopular opportunities – even if it means taking on government itself.
And in the Land of Unicorns, life sciences companies moving into previously prohibited markets are seen as a particularly intriguing opportunity.
The potential of psychedelics as potential treatment for mental healthcare is quickly being mainstream and there is definitely a sweeping change in attitudes towards psychedelics.
Silicon Valley investors know it.
These new media titans (and their massive audiences) know it.
And investors are waking up to the potentially lucrative futures of psychedelics too.
We’ve uncovered some of the fastest-moving psychedelic stocks before they moved and, given the way psychedelic stocks are moving, will find plenty more in the future too.
Disclosure: Mind Cure Health is a client of Psychedelic Stock Watch
Disclaimer:
Please see our full PRIVACY POLICY
The content on Psychedelic Stock Watch is not personalized investment advice. Our employees strive to give smart, stimulating commentary, but are not licensed to address or give advice on individual investment situations. Nothing you receive from Psychedelic Stock Watch should be considered personal investment advice. Any investments recommended by Psychedelic Stock Watch should only be made after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. All investments carry risk of significant loss.
Please see full disclaimers at https://psychedelicstockwatch.com/ applicable to all content provided by PSW , wherever published or re-published: https://psychedelicstockwatch.com/statements-policies
Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This release/advertorial does not constitute an offer or solicitation to buy or sell any securities or individualized investment advice. This is a native advertisement, meaning it is an informational paid marketing piece. PsychedelicStockWatch.com (PSW) makes no recommendation that the securities of the issuers profiled or discussed on this website should be purchased, sold or held by viewers, whether or not viewers learn of the profiled issuers through our website or otherwise. Please review all investment decisions with a licensed investment advisor.
PSW receives media support and payments from the issuer or third-party companies that have contracted with the issuer ranging from approximately $25,000 to $150,000 to publish and/or distribute advertisements on behalf of the issuer. The issuer and/or third-party companies that have contracted with the issuer have not promised exclusivity to PSW and may hire additional publishers or advertisers on behalf of the issuer. PSW retains any excess sums after expenses as its compensation. PSW may be paid for services using cash, options, restricted shares, free-trading shares, or shares of other unrelated issuers, and thus PSW and its owners, operators and affiliates may benefit from any increase in the share prices of the profiled issuers.
PSW and/or its owners, operators and affiliates make no representations about their short-term or long-term investment horizons and may be selling shares of stock at the same time the profile (or other information) is being disseminated to potential investors; PSW is under no obligation to, and will not, advise any party when it or its affiliates decide to buy or sell shares. Investors must make all investment decisions based on their own judgment of the market and the particular securities.
This release/advertorial contains forward-looking statements that involve risks and uncertainties. This release/advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured issuer. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s),” “anticipate(s),” “plan(s),” “expect(s),” “project(s),” “will,” “make,” “told,” “could,” “might,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the issuer to differ materially from these indicated by such forward-looking statements. Certain statements contained herein are forward-looking statements as defined in Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the issuer or PSW or contained in this release/advertorial are not guarantees of future performance, and that the issuer’s actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to update any statements made herein. Differences in results can be caused by various factors including, but not limited to, the issuer’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this release/advertorial contains “forward-looking statements.” Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. More information on the issuer that is the subject of this release/advertorial may be found at http://www.sec.gov where readers can review all public filings submitted by the issuer. PSW is not a certified financial analyst, investment advisor, broker/dealer, or licensed in the securities industry in any manner. The information in this advertorial is subjective opinion and may not be complete, accurate or current and was paid for by the issuer, creating a potential conflict of interest.